Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab versus ustekinumab in moderate to severe plaque psoriasis
NL-OMON41309Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Apr 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in plaque psoriasis comparing Secukinumab arm with Ustekinumab arm (2 arms). Primary endpoint: PASI 90 at week 16. Started Apr 2014; status: active, not recruiting.
02
Drugs
secukinumabustekinumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NL-OMON41309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41309.